Leukos Biotech, a Barcelona, Spain-based biotechnology company, raises €3.5m in funding.
The round was led by Inveready with participation from Dr. Enrique Llaudet, who joined Leukos as CEO.
Founded in October 2015 by the Josep Carreras Leukaemia Research Institute and by expert in Leukaemia and stem cells Dr. Ruth M. Risueño, Leukos will develop a novel class of drugs around a newly discovered therapeutic target that selectively destroys Leukemic Stem Cells.
The company intends to use the funds to advance a first candidate into clinical trials for Acute Myeloid Leukaemia for patients who are 60 years old or over and that are not suitable for bone marrow transplant or aggressive chemotherapy.
Leukos will also develop a pipeline of follow up candidates against Leukaemia Stem Cells in other types of Leukaemia.